SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Another_Voice_2 who wrote (10079)4/17/2018 8:45:49 PM
From: Kirk ©  Respond to of 12873
 
He owns at least 2,005,366 shares.
Is there anything you can point to that shows he has a concern for shareholders?
finance.yahoo.com

That is about 4 yrs pay at $1....

He and his CFO wife probably have a bundle of options too...

finance.yahoo.com

Key ExecutivesNameTitlePayExercisedYear Born
Dr. Anil R. DiwanChairman, Pres, Acting CEO & Sec.447.92kN/A1959
Ms. Meeta R. Vyas SB, MBAChief Financial Officer129.6kN/A1959
Dr. Eugene SeymourChief Exec. Officer Emeritus447.92kN/A1941
Dr. Randall W. Barton Ph.D.Chief Scientific Officer & Chief Regulatory OfficerN/AN/A1947
Dr. Jayant Tatake Ph.D.VP of R&DN/AN/AN/A



To: Another_Voice_2 who wrote (10079)4/17/2018 8:52:30 PM
From: BoredMember  Read Replies (2) | Respond to of 12873
 
He fully funded the purchase of the facility with his own money and then sold it back at cost.

He and his wife have dedicated years to this venture, and remember, she gave up a very successful career with GE, McKinsey and other blue chip firms.

He has granted Nanoviricides all rights to market and sell the finished treatments for a mere 30 percent on his expenses to bring the product to fruition and market.

He tirelessly is in the lab training and supervising the many, many Theracour employees that are diligently working on getting the nanoviricides optimized.

He is a passionate and articulate spokesperson and champion for the company at public and private events.

Need I say more?